Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine prophylaxis to prevent renal impairment after on-pump CABG
2006-006815-62Phase 4Terminated
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic kidney disease (CKD) and coronary arteriosclerosis comparing N-acetylcysteine prophylaxis with Placebo / standard care (2 arms). Primary endpoint: Change in serum creatinine during first 48 hours postoperatively. Started Apr 2007; status: terminated.
02
Drugs
acetylcysteine
03
Conditions
chronic kidney disease (CKD)coronary arteriosclerosis
Beyond the preview
Go deeper on 2006-006815-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006815-62.